Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607146 | 0.82 | TDP1 (0.42) | ALDH1A1 | |
| SCHEMBL10369500 | 0.81 | GRIA4 (0.42) | FFAR1KIF11 | |
| SCHEMBL28858449 | 0.79 | CES2 (0.39) | PDE2ACES2CES1ACP3CNR2 | |
| SCHEMBL14369491 | 0.78 | PDE2A (0.48) | PDE2ACES2CES1MC4RACP3 | |
| SCHEMBL13126259 | 0.78 | PDE2A (0.48) | PDE2ACES2CES1MC4RACP3 | |
| SCHEMBL4839555 | 0.77 | KIF11 (0.43) | PDE2AFFAR1KIF11 | |
| SCHEMBL28347282 | 0.77 | PDE2A (0.52) | PDE2ACES2CES1MC4RALDH1A1 | |
| SCHEMBL435755 | 0.77 | PDE2A (0.52) | PDE2ACES2CES1MC4RALDH1A1 | |
| SCHEMBL27528113 | 0.77 | PDE2A (0.47) | PDE2ACES2CES1MC4RACP3 | |
| SCHEMBL13622230 | 0.77 | PDE2A (0.52) | PDE2ACES2CES1MC4RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4583876-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | Juno Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152717-A | Combination of T cell therapy and continuous or intermittent DGK inhibitor administration | 朱诺治疗学股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024054944-A1 | COMBINATION OF A T CELL THERAPY AND CONTINUOUS OR INTERMITTENT DGK INHIBITOR DOSING | JUNO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117693508-A | Combination of T cell therapy and DGK inhibitors | 朱诺治疗学股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4301755-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Juno Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023184327-A1 | KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-03-23 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| EP-4076529-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115243721-A | Combination of DGK inhibitors and checkpoint antagonists | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2022187406-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4021901-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021127554-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | PDE2A 1693/4885CES2 4254/4885CES1 3187/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PDE2A 1693/4885CES2 4254/4885CES1 3187/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PDE2A 1693/4885CES2 4254/4885CES1 3187/4885 |
| US-20240108654-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | DGKG, DGKA, DGKI | PDE2A 2589/4885CES2 2442/4885CES1 1019/4885 |
| US-20230089255-A1 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | DGKA, DGKG, DGKB | PDE2A 1720/4885CES2 4243/4885CES1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.